Liposomal Sustained-Release Delivery Systems for Intravenous Injection. II. : Design of Liposome Carriers and Blood Disposition of Lipophilic Mitomycin C Prodrug-Bearing Liposomes

スポンサーリンク

概要

• 論文の詳細を見る

• Various types of unilamellar liposomes possessing a narrow size distribution were prepared by controlled dialysis and their blood clearance was studied in mice and rats to assess their suitability as drug carriers for intravenously injectable liposomal sustained-release delivery systems. Also, the utility of these liposomal carrier systems combined with lipophilic prodrugs of mitomycin C (MMC) was evaluated. The fate of the liposomes was monitored uisng N-4-nitrobenzo-2-oxa-1,3-diazole-dipalmitoylphosphatidylethanolamine (NBD-PE), a liposomal membrane marker. The effect of vesicle size on the blood clearance was investigated for neutral liposomes. Small-sized (S-) liposomes (90±15 nm) were cleared slowly compared with medium-sized (M-) liposomes (181±31 nm) and large-sized liposomes (281±38 nm). Surface charge was also an important determinant of the disposition of small-sized liposomes. S-Liposomes were retained in the circulation longer than positively (S^+-) and negatively (S^--) charged liposomes. The integrity of S-liposomes in the circulation was examined by simultaneous determination of NBD-PE and carboxyfluorescein (CF) entrapped in the liposomal membrane and liposomal aqueous phase, respectively. CF administered in the liposome-encapsulated form was cleared slowly in a fashion similar to NBD-PE, while free CF, administered as an aqueous solution, was rapidly removed from the circulation. These results reveal that S-liposomes show the best pharmacokinetic properties as a carrier vehicle for intravenously injectable sustained-release delivery systems. S-Liposomes loaded with the lipophilic MMC prodrug, N-(cholesteryloxycarbonyl)glycyl MMC or cholesteryloxyacetyl MMC, successfully gave sustained blood levels of the parent drug following intravenous injection. Thus, the potential utility of MMC prodrug-bearing S-liposomes as an intravenously injectable MMC sustained-release dosage form was demonstrated.

• 社団法人日本薬学会の論文
• 1988-09-25

著者

• 藤崎 二朗

  Exploratory Research Laboratories Fujisawa Pharmaceutical Company Ltd.

• 藤崎 二郎

  藤沢薬品工業探索研究所

• 藤崎 二郎

  藤沢薬品工業

• 徳永 雄二

  Exploratory Research Laboratories, Fujisawa Pharmaceutical Company, Ltd.,

• 岩佐 知明

  Exploratory Research Laboratories, Fujisawa Pharmaceutical Company, Ltd.,

• 沢居 清治

  Exploratory Research Laboratories, Fujisawa Pharmaceutical Company, Ltd.,

• 加賀山 彰

  Exploratory Research Laboratories, Fujisawa Pharmaceutical Company, Ltd.,

• 藤崎 二郎

  Exploratory Research Laboratories, Fujisawa Pharmaceutical Company, Ltd.,

• 加賀山 影

  Exploratory Research Laboratories, Fujisawa Pharmaceutical Company, Ltd.,

• 徳永 雄二

  Pharmaceutical Institute, Tohoku University

• 徳永 雄二

  藤沢薬品工業 開発第二研

• 沢居 清治

  Exploratory Research Laboratories Fujisawa Pharmaceutical Company Ltd.

• 加賀山 彰

  Exploratory Research Laboratories Fujisawa Pharmaceutical Company Ltd.

• 岩佐 知明

  Exploratory Research Laboratories Fujisawa Pharmaceutical Company Ltd.

関連論文

• Regional Capacities of Gastrointestinal Absorption and Lymphatic Transport for Lipid-Soluble Dyes in Rats
• Potential Absorption of Heparin from the Small Intestine and the Large Intestine in the Presence of Monoolein Mixed Micelles
• キット製剤の将来展望(E・薬剤学, 製剤学, 病院薬学)
• Liposomal Sustained-Release Delivary Systems for Instravenous Injection. V. : Biological Disposition of Liposome-Entrapped Lipophilic Prodrug of 1-β-D-Arabinofuranosylcytosine
• Liposomal Sustained-Release Delivery Systems for Intravenous Injection. IV. : Antitumor Activity of Newly Synthesized Lipophilic 1-β-D-Arabinofuranosylcytosine Prodrug-Bearing Liposomes
• Liposomal Sustained-Release Delivery Systems for Intravenous Injection. III. : Antitumor Activity of Lipophilic Mitomycin C Prodrug-Bearing Liposomes
• Liposomal Sustained-Release Delivery Systems for Intravenous Injection. II. : Design of Liposome Carriers and Blood Disposition of Lipophilic Mitomycin C Prodrug-Bearing Liposomes
• Liposomal Sustained-Release Delivery Systems for Intravenous Injection. I. : Physicochemical and Biological Properties of Newly Synthesized Lipophilic Derivatives of Mitomycin C
• INDIRECT ELECTROREDUCTIVE CYCLIZATION FOR SYNTHESES OF KEY INTERMEDIATES OF SEVERAL INDOLE AND IPECAC ALKALOIDS
• Effect of Some Ionic and Nonionic Surfactants on the Intramuscular Absorption of Isonicotinamide
• O-66 セファメジンαノンバイアルキットの製剤設計 (2) : 製剤特性と機能性評価
• O-65 セファメジンαノンバイアルキットの製剤設計 (1) : 設計コンセプトと有用性評価
• 放出開始時間制御型経口投与システム (TES) の設計
• Development of a Novel Drug Release System, Time-Controlled Explosion System (TES). III. Relation between Lag Time and Membrane
• セファメジンαノンバイアルキットの容器設計と品質保証
• Development of a Novel Drug Release System, Time-Controlled Explosion System (TES). II. Design of Multiparticulate TES and in Vitro Drug Release Properties
• Biopharmaceutical Study of the Hepato-biliary Transport of Drugs. IV. Development of the Method to Investigate the Process of the Active Secretion of Drugs from the Hepatocytes into the Bile Canaliculi and Its Application to the Biliary Excretion of Organ

もっと見る 閉じる

スポンサーリンク